Citigroup Increases Insulet (NASDAQ:PODD) Price Target to $275.00

Insulet (NASDAQ:PODD) had its price target hoisted by Citigroup from $250.00 to $275.00 in a report published on Tuesday, Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

Several other equities research analysts also recently commented on the stock. OTR Global reiterated a mixed rating on shares of Insulet in a research report on Monday, June 10th. UBS Group boosted their price objective on shares of Insulet from $211.00 to $223.00 and gave the stock a neutral rating in a research note on Friday, August 9th. Barclays raised their target price on Insulet from $200.00 to $220.00 and gave the stock an equal weight rating in a research report on Monday, August 12th. Canaccord Genuity Group upped their price target on Insulet from $236.00 to $269.00 and gave the company a buy rating in a research report on Wednesday, September 25th. Finally, Piper Sandler raised their price objective on Insulet from $230.00 to $285.00 and gave the stock an overweight rating in a research report on Tuesday, September 17th. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Insulet currently has a consensus rating of Moderate Buy and a consensus target price of $234.60.

Insulet Stock Down 0.0 %

PODD stock opened at $229.94 on Tuesday. The firm has a 50-day moving average price of $209.88 and a 200-day moving average price of $192.02. Insulet has a 12 month low of $125.82 and a 12 month high of $243.98. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36. The stock has a market capitalization of $16.10 billion, a P/E ratio of 69.68, a price-to-earnings-growth ratio of 4.34 and a beta of 1.21.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The company had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. The business’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.38 EPS. As a group, equities research analysts anticipate that Insulet will post 3.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Diversified Trust Co grew its stake in Insulet by 90.9% in the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock valued at $1,842,000 after acquiring an additional 4,348 shares during the period. SG Americas Securities LLC increased its stake in Insulet by 349.3% during the 1st quarter. SG Americas Securities LLC now owns 29,575 shares of the medical instruments supplier’s stock valued at $5,069,000 after purchasing an additional 22,993 shares in the last quarter. Duality Advisers LP raised its holdings in Insulet by 89.4% during the first quarter. Duality Advisers LP now owns 19,131 shares of the medical instruments supplier’s stock worth $3,279,000 after buying an additional 9,029 shares during the last quarter. Diversify Advisory Services LLC bought a new position in shares of Insulet in the first quarter valued at $1,043,000. Finally, Intech Investment Management LLC lifted its stake in shares of Insulet by 113.8% in the first quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock valued at $1,140,000 after buying an additional 3,539 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.